Contact

RUCONEST® Efficacy

Clinical trials

RUCONEST® provides fast, effective, sustained symptom relief with just one dose1-4

FAST

Median time to start of symptom relief was <2 hours* in clinical trials, even in the case of severe attacks and regardless of attack location1-3

EFFECTIVE

96% of attacks were treated with just one dose,** even in the case of severe attacks and regardless of attack location (215/224 attacks in 44 patients)1

SUSTAINED

For at least 3 DAYS n=68 (259 of a total of 280 attacks)†4‡ One dose of RUCONEST® stopped 93% of attacks (259/280 in 68 patients) for at least 3 days4

*Confirmed by the consensus of HAE experts at Pharming Advisory Board meeting on 7th March 2022. **1 or 2 vials depending on the patient weight. †Dosing of RUCONEST® is weight dependent and one dose is, therefore, based on patient weight as follows; <42kg = up to 1 vial, 42-84kg = 50 U/kg (up to 2 vials), >84kg = 2 vials; ‡RUCONEST® is indicated for treatment of acute angioedema attacks in adults and adolescents with HAE due to C1-INH deficiency.⁵ C1-INH: C1 esterase inhibitor; HAE: hereditary angioedema.

Patients can be confident that RUCONEST® works, even in the case of severe attacks and regardless of their location1,3,6,7

HAE: Hereditary Angioedema; OFPL, oro-facial pharyngeal-laryngeal.
Note: Results are obtained from pooled analysis of data from studies C1 1205 and C1 1310. Adapted from Baker et al., 2018.⁶

*Attacks with 72 hour, post dose follow up data. Sustained response defined as a response (≥20 mm decrease of VAS scores at 2 consecutive time points for 4 hours post treatment) that was not associated with an increase of ≥20 mm or onset of new attack symptoms within 72 hours post dose6. RUCONEST® is indicated for treatment of acute angioedema attacks in adults and adolescents with HAE due to C1-INH deficiency.⁵

Real world

Real world evidence demonstrates that RUCONEST® provides sustained relief for all HAE attacks in just one dose in multiple locations8*

For a European patient registry involving:

71 patients

9 countries

2,351 HAE attacks

99.8% of attacks were resolved in just one dose of RUCONEST® regardless of attack location.8

RUCONEST® gives sustained relief for all HAE attacks in just one dose in multiple locations8*

All patients (N=71)

All attacks
(N=2,356)

First attack
(n=71)

Single location
(N=2,242)

Two locations
(N=109)

Three locations
(N=5)

Dose
Mean number of units (U) U/kg

3,307
43.3

3,107
40.7

3,336
43.6

2,749
38.0

2,520
35.1

Number of doses, n (%) One

2,351 (99.8)

70 (98.6)

2,239 (99.9)

107 (98.2)

5 (100)

*RUCONEST® is indicated for the treatment of acute angioedema attacks in adults and adolescents with HAE due to C1-INH deficiency.⁵

References
1. Li H, et al. J Allergy Clin Immunol Pract. 2015;3(3):417-423.
2. Riedl M, et al. Ann Allergy Asthma Immunol. 2013;110(4):295-299.
3. Riedl M, et al. Ann Allergy Asthma Immunol. 2014;112(2):163-169.
4. Bernstein J, et al. Ann Allergy Asthma Immunol. 2017;118(4):452-455.
5. RUCONEST® SmPC. Jun 2021.
6. Baker J, et al. Allergy Asthma Proc. 2018;39(5):359-364.
7. Riedl M, et al. Allergy Asthma Proc. 2017;38(6):462-466.
8. Valerieva A, et al. World Allergy Organ J. 2021;14(4):100535.